TY - JOUR
T1 - An analysis of the physiological FDG uptake pattern in the stomach
AU - Koga, Hirofumi
AU - Sasaki, Masayuki
AU - Kuwabara, Yasuo
AU - Hiraka, Kiyohisa
AU - Nakagawa, Makoto
AU - Abe, Koichiro
AU - Kaneko, Koichiro
AU - Hayashi, Kazutaka
AU - Honda, Hiroshi
PY - 2003/12
Y1 - 2003/12
N2 - The purpose of this study was to clarify the normal gastric FDG uptake pattern to provide basic information to make an accurate diagnosis of gastric lesions by FDG PET. We examined 22 cases, including 9 of malignant lymphoma, 8 of lung cancer, 2 of esophageal cancer, and 3 of other malignancies. No gastric lesions were observed in any of the 22 cases on upper gastrointestinal examinations using either barium meal or endoscopic techniques. The intervals between FDG PET and the gastrointestinal examination were within one week in all cases. The stomach regions were classified into the following three areas: U (upper)-area, M (middle)-area, and L (lower)-area. The degree of FDG uptake in these three gastric regions was qualitatively evaluated by visual grading into 4 degrees, and then a semiquantitative evaluation was carried out using the standardized uptake value (SUV). Based on a visual grading evaluation, the mean FDG uptake score in the U-, M-, and L-areas was 1.14 ± 0.96, 0.82 ± 0.96, and 0.36 ± 0.49 (mean ± S.D.), respectively. The FDG uptake scores obtained in the three areas were significantly different (Friedman test, p < 0.05). Furthermore, the rank order of the FDG uptake score in each case (U ≥ M ≥ L) was found to be statistically significant (Cochran-Armitage trend test, p < 0.05). The mean SUVs of 11 cases in the three areas were 2.38 ± 1.03, 1.91 ± 0.71, and 1.34 ± 0.44 (mean ± S.D.), respectively. The SUV in the U-area was significantly higher than that in the L-area (Friedman test, p < 0.05). A significant difference in FDG uptake was observed among the three gastric areas, and the FDG uptake extent in all cases was U > M > L. In conclusion, the physiological gastric FDG uptake was significantly higher at the oral end. A stronger gastric FDG uptake at the anal end may therefore be suggestive of a pathological uptake.
AB - The purpose of this study was to clarify the normal gastric FDG uptake pattern to provide basic information to make an accurate diagnosis of gastric lesions by FDG PET. We examined 22 cases, including 9 of malignant lymphoma, 8 of lung cancer, 2 of esophageal cancer, and 3 of other malignancies. No gastric lesions were observed in any of the 22 cases on upper gastrointestinal examinations using either barium meal or endoscopic techniques. The intervals between FDG PET and the gastrointestinal examination were within one week in all cases. The stomach regions were classified into the following three areas: U (upper)-area, M (middle)-area, and L (lower)-area. The degree of FDG uptake in these three gastric regions was qualitatively evaluated by visual grading into 4 degrees, and then a semiquantitative evaluation was carried out using the standardized uptake value (SUV). Based on a visual grading evaluation, the mean FDG uptake score in the U-, M-, and L-areas was 1.14 ± 0.96, 0.82 ± 0.96, and 0.36 ± 0.49 (mean ± S.D.), respectively. The FDG uptake scores obtained in the three areas were significantly different (Friedman test, p < 0.05). Furthermore, the rank order of the FDG uptake score in each case (U ≥ M ≥ L) was found to be statistically significant (Cochran-Armitage trend test, p < 0.05). The mean SUVs of 11 cases in the three areas were 2.38 ± 1.03, 1.91 ± 0.71, and 1.34 ± 0.44 (mean ± S.D.), respectively. The SUV in the U-area was significantly higher than that in the L-area (Friedman test, p < 0.05). A significant difference in FDG uptake was observed among the three gastric areas, and the FDG uptake extent in all cases was U > M > L. In conclusion, the physiological gastric FDG uptake was significantly higher at the oral end. A stronger gastric FDG uptake at the anal end may therefore be suggestive of a pathological uptake.
UR - http://www.scopus.com/inward/record.url?scp=1042279672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=1042279672&partnerID=8YFLogxK
U2 - 10.1007/BF02984984
DO - 10.1007/BF02984984
M3 - Article
C2 - 14971621
AN - SCOPUS:1042279672
SN - 0914-7187
VL - 17
SP - 733
EP - 738
JO - Annals of Nuclear Medicine
JF - Annals of Nuclear Medicine
IS - 8
ER -